IMBdx has partnered with Inocras to improve cancer patient care in the US by enhancing genomic analysis used in cancer profiling and providing broader diagnostic options.
The partnership will focus on expanding IMBdx’s liquid-biopsy-based cancer diagnostics in the US through Inocras. This collaboration aims to present a fresh approach to patient care by pairing whole genome data with liquid biopsy. It provides an alternative to traditional tissue biopsy when not feasible. The goal is to create a seamless and effective pathway for cancer care through these advanced diagnostic services.
Inocras, formerly Genome Insight, is a biotechnology company that provides whole genome sequencing (WGS) and bioinformatics solutions. Inocras provides personalized diagnostic solutions focusing on genetically driven diseases such as cancer and rare diseases. The company's key products are CancerVision and RareVision, WGS-based tests designed to offer a detailed analysis of a patient's genetic makeup to support treatment planning and clinical trial matching.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.